Clinical Trial

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Name: Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab — clinical trial record (NCT06167642)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Enrolling by Invitation

View on ClinicalTrials.gov →

Summary

This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.

Trial Details

NCT Number	NCT06167642
Lead Sponsor	Johns Hopkins University Collaborators: Novartis
Conditions	Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
Enrollment	75 participants
Start Date	2023-05-22
Primary Completion	2027-03 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-10